Making top-quality cancer care accessible to all.100% free, no account required.

Understanding Cervical Cancer Treatment That Supports Future Pregnancy Options

NCT04016389 · Recruiting
About this trial

This study focuses on women with invasive cervical cancer who want to maintain their ability to have children after treatment. It looks at whether giving chemotherapy before surgery can help keep fertility. Participants will receive chemotherapy drugs that are often used to treat cervical cancer, followed by surgery to remove the cervix while keeping the uterus intact.

Locations and contact

This trial is running at 4 locations in 2 countries. 3 of them are currently recruiting.

United States1 location
  • MD Anderson Cancer CentreHouston, TexasTerminated
Canada3 locations · 3 recruiting
  • L'Hôtel-Dieu de QuébecQuébec, QuebecRecruiting
  • Princess Margaret Cancer CentreToronto, OntarioRecruiting
  • Sunnybrook Health Sciences CentreToronto, OntarioRecruiting
Who to ask about joining
Who can join

Women aged 18 to 40 who have invasive cervical cancer and wish to preserve their fertility can join. They must be premenopausal and have not had prior cancer treatments. The trial team will confirm who is eligible before participation.

What happens during the trial

Participants will receive chemotherapy with either cisplatin or carboplatin along with paclitaxel for three cycles. After this treatment, they will have their response checked. If the treatment works, they will have a surgery called a trachelectomy. Depending on their condition post-surgery, they may need additional treatment.

The trial team

The trial is sponsored by the University Health Network in Toronto, with collaboration from Hotel Dieu Hospital and The Netherlands Cancer Institute. Dr. Stephanie Lheureux from Princess Margaret Cancer Centre is the principal investigator.

Important dates

This trial started on February 11, 2020, and is currently recruiting participants. It is expected to be completed by December 2028.

Additional information

The trial's ID number is NCT04016389. It is not FDA-regulated and aims to include about 31 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals